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Abstract
Background: Medicines management in care homes requires significant improvement. CHIPPS was a cluster
randomised controlled trial to determine the effectiveness of integrating pharmacist independent prescribers into
care homes to assume central responsibility for medicines management. This paper reports the parallel mixed-
methods process evaluation.
Method: Intervention arm consisted of 25 triads: Care homes (staff and up to 24 residents), General Practitioner
(GP) and Pharmacist Independent Prescriber (PIP). Data sources were pharmaceutical care plans (PCPs), pharmacist
activity logs, online questionnaires and semi-structured interviews. Quantitative data were analysed descriptively.
Qualitative data were analysed thematically. Results were mapped to the process evaluation objectives following
the Medical Research Council framework.
Results: PCPs and activity logs were available from 22 PIPs. Questionnaires were returned by 16 PIPs, eight GPs, and
two care home managers. Interviews were completed with 14 PIPs, eight GPs, nine care home managers, six care
home staff, and one resident. All stakeholders reported some benefits from PIPs having responsibility for medicine
management and identified no safety concerns. PIPs reported an increase in their knowledge and identified the
value of having time to engage with care home staff and residents during reviews. The research paperwork was
identified as least useful by many PIPs. PIPs conducted medication reviews on residents, recording 566 clinical
interventions, many involving deprescribing; 93.8% of changes were sustained at 6 months. For 284 (50.2%)
residents a medicine was stopped, and for a quarter of residents, changes involved a medicine linked to increased
falls risk. Qualitative data indicated participants noted increased medication safety and improved resident quality of
life. Contextual barriers to implementation were apparent in the few triads where PIP was not known previously to
the GP and care home before the trial. In three triads, PIPs did not deliver the intervention.
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Conclusions: The intervention was generally implemented as intended, and well-received by most stakeholders.
Whilst there was widespread deprescribing, contextual factors effected opportunity for PIP engagement in care
homes. Implementation was most effective when communication pathways between PIP and GP had been
previously well-established.
Trial registration: The definitive RCT was registered with the ISRCTN registry (registration number ISRCTN 17847169).
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Background
Medicines management in care homes within the United
Kingdom (UK) has been found to require significant im-
provement both from the perspective of quality assur-
ance processes [1] clinical safety and effectiveness. The
2009 CHUMS study, in which medicines systems and
their management process were observed in a large
number of homes across England, identified that 70% of
residents experienced at least one medication error every
day, ranging from sub-optimal prescribing to inadequate
medication monitoring, administration, storage and re-
cording [2]. Problems with over-prescription of antipsy-
chotics [3], laxatives [4], under-prescribing of analgesics
[5] and unnecessary prescribing of medicines increasing
the risk of falls [6] or anticholinergic burden [7] are all
commonly reported within the international literature.
Effective, safe and cost-effective models for enhancing
pharmaceutical care and clinical outcomes within care
homes have been identified as still requiring develop-
ment [8, 9].
We proposed that the integration of a pharmacist with
independent prescribing rights (pharmacist independent
prescriber-PIP) into care homes to assume central re-
sponsibility for medicines-related activities might pro-
vide a model of care which would address both quality
assurance and clinical concerns. The Care Home Inde-
pendent Prescribing Pharmacist Study (CHIPPS) [10]
was a programme of work which, in line with established
guidance [11], developed and evaluated a complex
pharmacist-led intervention of such a service. First, we
developed a service specification through extensive
stakeholder engagement [12]. Stakeholders agreed that
the components of the PIP service should include medi-
cine review (including deprescribing and minimising the
potential for adverse effects from medicines) and
pharmaceutical care planning, authorisation of monthly
repeat prescriptions, supporting the optimisation of or-
dering and storage systems, supporting care home staff
with medicines administration and training care home
staff [13]. The PIPs were expected to become a central
resource for all care home medicines activities and con-
sequently, they required effective processes for commu-
nicating with the medical practice, care home and the
supplying community pharmacy. The final service speci-
fication (additional file 1) included both ‘essential’ and
‘discretionary’ activities depending on identified local
needs.
A training programme was developed to equip phar-
macists with requisite knowledge and skills to assume
responsibility for prescribing for a frail, older population,
with a focus on reducing risk of falls. It comprised two
taught days followed by 6 days of self-directed activities
focussing on integration of PIPs into teams and collation
of evidence for formal competency assessment and sign-
off [14].
A logic model was developed in the initial stages of
the project to propose a theoretical basis for the inter-
vention. A standard approach was used to identify ap-
propriate outcomes for the main trial. The final outcome
set included medication appropriateness, adverse drug
events, prescribing errors, falls, quality of life, all-cause
mortality and admissions to hospital and a health eco-
nomic assessment [15].
The service model and research design were subse-
quently tested in a feasibility study in four locations,
each with one PIP, medical practice and cohort of ten
care home residents (triad) [16]. Learning from this
study resulted in a refined protocol for the definitive
cluster randomised controlled trial comparing the effect-
iveness and cost effectiveness of a pharmacist independ-
ent prescriber managing care home residents’ medicines
compared to usual GP-led care, with reduction in falls a
primary outcome. The definitive trial was conducted
across four sites within three of the four UK devolved
nations, over 6 months. In the intervention arm, each
PIP was allocated approximately 20 residents and reim-
bursed for the equivalent of four hours a week. To en-
able management of recruitment, training and data
collection, the study was delivered over four phases
within a two-year study period (2018–20).
To understand the exact way the intervention was im-
plemented in practice, and the implications of this for
the trial outcomes we designed a mixed-method process
evaluation [17], following the Medical Research Coun-
cil’s process evaluation framework [11]. The objectives
were:
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1. To describe the intervention as delivered in terms
of quality, quantity, adaptations and variations
across triads and time.
2. To explore the effects of individual intervention
components on the primary outcomes.
3. To investigate the mechanisms of impact.
4. To describe the perceived effectiveness of relevant
intervention components (including PIP training
and care home staff training) from participant (GP,
care home, PIP and resident/relative) perspectives.
5. To describe the characteristics of GP, care home,
PIP and resident participants to assess reach.
6. To estimate the extent to which intervention
delivery was normalised among the intervention
healthcare professionals and related practice staff
[17].
Quantitative trial data collected to describe the effect-
iveness of the intervention (falls, EQ-5D-5L, Barthel
scores, drug burden index (DBI), mortality, hospitalisa-
tion and adverse events) (objective 2) are not reported
here, but will be reported in the main RCT paper (sub-
mitted for separately). The process evaluation was
undertaken prior to the analyses of the trial outcomes to
ensure the researchers’ interpretations were not influ-
enced by the results of the trial.
Method
To address the evaluation objectives, this mixed-
methods process evaluation used qualitative and quanti-
tative approaches to describe the processes of interven-
tion implementation, the mechanisms of impact, the
outcomes and the contextual factors, in the intervention
triads.
Data collection, management, and analysis
We collated data on PIP, GP, and care home demo-
graphics across the four locations. Data analysis was an
iterative process with each data set first analysed separ-
ately by specialist qualitative researchers before synthe-
sis. The process evaluation objectives [17] were our
anchor questions [18] guiding the analysis. Trial records
and questionnaire results provided quantifiable data on
PIP activity; we aligned this with the qualitative accounts
to provide contextual background to numerical data on
the facilitators and barriers to implementation, the
mechanisms of carrying out the intervention, and per-
ceived usefulness of the intervention outcomes.
Pharmaceutical care plans (PCPs)
During the intervention PIPs completed and returned
pharmaceutical care plans which detailed biomedical
monitoring requests, medicine review and actions at
resident level. Three hundred and seventy PCPs are
included in this process evaluation (see below for ex-
planation of missing PCPs). Trial geriatricians reviewed
a random 20% sample of PCPs, weighted to the start of
each intervention period, to assess safety. Two research
pharmacists within the research team reviewed 185
(50%) PCPs (105 reviewed independently in duplicate)
for ‘potential missed opportunities’ based on the guide-
lines on appropriate prescribing used by the PIPs, which
included checking that an appropriate indication, recom-
mended biomedical monitoring and regular review of
ongoing need had been recorded. The term ‘potential
missed opportunity’ is used because without access to
full resident notes and with no insight into conversations
which might have taken place, there could have been
valid reasons why a guideline recommended change had
not been made. To explore the effects of individual
intervention components on the primary outcomes, a
doctoral student with a pharmacy qualification cate-
gorised the medication changes by British National For-
mulary (BNF) therapeutic group [19], by causal link to
falls with Odds Ratios (OR) 1–1.5; 1.51–2; > 2 [20–22],
and by Drug Burden Index (DBI) [23]. The DBI is (a
dose-related measure of individual burden from anti-
cholinergic and sedative drug exposure) (≤ 0.5; 0.51–1;
1.01–1.5). All were reported as frequencies.
Activity logs
The PIPs logged their use of time, categorised by activity
type, on standard forms. The 10 categories were amal-
gamated into four groups: face-to-face time with resi-
dent; desk time on resident-related activity; other trial
activity; and travel time. All were summarised using de-
scriptive statistics.
Questionnaires
Post-intervention, an online questionnaire was sent
via the REDCap data management system [24] to 88
stakeholders: 25 PIPS, 25 GPs, 38 care home man-
agers. Likert scale measures and open text boxes were
used to examine perceptions of training, variety and
frequency of tasks delivered, opinions on usefulness
of different parts of the service, team communication
and relationships. The questionnaire also included the
NoMad survey instrument [25] which captures data
relevant to the four Normalization Process Theory
domains [26]; NoMAD data is not reported here. The
questionnaire was piloted on stakeholders from the
feasibility study; no changes were made. The Likert
scale responses were treated as ordinal data, with fre-
quency across stakeholder groups displayed as bar
charts. The open-text responses were added to the
interview data on NVivo [27].
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Interviews
Emails inviting all 88 stakeholders to interview were sent
to the intervention triads: 25 PIPs, 25 GPs, 38 Care
home managers (2 care homes recruited to the interven-
tion were no longer contactable due to closure). Care
home managers were asked to share the invitation to
take part in an interview with care staff, residents and
their relatives involved in the intervention. Following
consent from each participant, semi-structured inter-
views were conducted which explored participants’ views
of the PIP service (including barriers and facilitators to
implementation, impact on workload, and working rela-
tionships focusing on communication, and acceptability).
Topic guides (Additional file 2) were developed specific
to each stakeholder group with those for residents and
family reviewed by PPI members for clarity.
LD and LB undertook interviews either face-to-face or
by telephone, between May 2019 and March 2020. Inter-
views were audio-recorded and transcribed verbatim.
Data were thematically analysed drawing on the stepped
approach suggested by Braun and Clarke [28]. Following
familiarisation with the data, a coding framework was
developed which aligned with the process evaluation
framework and drew on principles of Normalization
Process Theory. The coding framework was agreed
within the multidisciplinary team. Coding was under-
taken independently by LB and LD who met fortnightly
to discuss differences in coding and come to a consen-
sus. During, this process some codes were merged and
others subdivided to explore similarities and differences
across stakeholders.
At all stages of the analysis process including develop-
ing the coding framework, considering contextual differ-
ences in experiences, and searching negative cases the
wider multidisciplinary study team, including clinical
and academic pharmacists and GPs, were consulted.
Results
Twenty-five intervention triads including 449 residents
were recruited to the trial from sites in Scotland (9 tri-
ads), Northern Ireland (5) and England: Yorkshire (6),
East Anglia (5). Three PIPs did not return any trial data
and were recorded as not delivering the intervention;
they were invited to complete the online questionnaire
and an interview, but none responded. Of the 22 PIPs
who provided the intervention for 6 months, 18 (82%)
were female. The median time practising as a prescriber
was 3 and half years with a range of 2 months to 16
years. Fifteen PIPs (68%) had worked in their triad GP
practice prior to the trial. Twelve PIPs delivered the
intervention in one care home, six PIPs across two care
homes and four PIPs across three care homes; three of
these were in Northern Ireland where care homes are
often supported by several GP practices. Thirteen PIPs
were allocated between 20 and 24 residents, 5 had 11–
19 residents, 4 had 10 or less residents. Table 1 presents
demographic data on sample. Additional file 3 contains
full details of PIP, and GP practice and care home
characteristics.
Main trial records (PCPs and activity logs) were col-
lected from 22 PIPs. Questionnaires were completed by
26 participants (30% return) across 21 intervention tri-
ads (PIP = 16; GP = 8; care home manager [CHM] =2).
Interview data were collected from 38 participants across
18 triads (PIP = 14; GP = 8; CHM = 9; care home staff
[CHS] = 6; Resident = 1). Eighteen participants com-
pleted both survey and interview (PIP = 13; GP = 3;
CHM = 2). Interviews lasted between 20 and 70 min. In
two triads, PIPs completed the intervention, but we were
unable to collect questionnaire or interview data from
any of the stakeholders. In the three triads where the
PIP did not complete the intervention the only data col-
lected was from one GP questionnaire.
Results are presented under four strands related to the
process evaluation objectives: 1) Intervention implemen-
tation (including adequacy of PIP training and the fidel-
ity of service delivery); 2) Mechanism of impact
(description of individual intervention components
which could have affected the trial outcomes); 3) Out-
comes (PIP, GP and care home staff perception of im-
pact of the intervention); 4) Contextual factors
(descriptions of barriers and facilitators to delivering the
intervention and adaptations and variations across tri-
ads). Illustrative quotes are drawn from open text boxes
in the questionnaire and interview.
Strand 1 intervention implementation (objectives 1,2,4)
Training for PIPs
In the questionnaire responses, 13 of 16 PIPs reported
that the training was sufficient. Three PIPs reported it
could be further enhanced by including more informa-
tion on how to use the PCPs and one requested more
examples of deprescribing. Having input from geriatri-
cians and the opportunities to discuss case studies were
reported as beneficial both in refreshing knowledge and
in adding to their understanding of geriatric medication.
During interviews, all PIPs (n = 14) reported that the
training, professional development and assessment
against a competency framework led to them feeling
confident and competent in their intervention role.
PIP delivery of intervention
Services provided Questionnaire data indicated the ex-
tent that PIPs delivered each of the essential intervention
activities. Medication review, pharmaceutical care plan-
ning and repeat prescription authorisation were
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frequently reported, with greater variation in the delivery
of other activities See Fig. 1.
Interview data indicated how individual decisions were
made about the feasibility of delivering activities identi-
fied as essential in the trial service specifications. If the
PIP was not an employee of the GP practice, this im-
pacted on their willingness to undertake some activities
e.g. authorising repeat prescriptions, ‘actually for six
months for me being there … it is kind of impossible I
think that bit’ PIP19. Similarly, the perceptions of the
PIP’s competence, both by the PIP and other stake-
holders was a factor whether a new prescription was ini-
tiated, ‘where there might be a clinical call, I think she’ll
leave that to the GP to sign’ GP14.
Information on delivery of ‘discretionary activities’ was
only asked in the PIP questionnaires, not those com-
pleted by other stakeholders (see Fig. 2). The most fre-
quent activities reported were answering medicine-
Table 1 Demographics by stakeholder
Recruited to: Intervention Post intervention questionnaire Post intervention interview
PIP (Pharmacist independent Prescriber)
Number of PIPs 25 16 14
Mean time as registered pharmacist 19 years (8–40 years) 21 years (8–40 years) 20 years (10–36 years)
Mean time as independent prescriber 56 months (1–192months) 65 months (1–192months) 58 months (1–192months)






Had previous care home experience 12 (48%) 6 (37.5%) 7 (50%)
GP practices
Number of GP practices 25 8 8
Employed intervention pharmacist prior to study 15 (60%) 3 (37.5%) 4 (50%)
Registered patients ≥10,000 9 (36%) 3 (37.5%) 3 (37.5%)
Care homes
Number of Care homes 40 2 care homes (2 staff) 11 care homes (15 staff)






Type of funding Private 34 (85%)














Fig. 1 PIP (n = 16) reported delivery of essential activities
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related enquiries, supporting medicine documentation
and medicine ordering.
Interview data and open text questionnaire responses
from the three stakeholder groups provided insights into
the variation in delivery of discretionary activities. While
one pharmacist spent a whole day undertaking stock
control after identifying gross over-ordering of appli-
ances, many others described this as an activity that
could be carried out by a pharmacy technician. Some
care homes reported they did not need some services
such as management of homely remedies or staff train-
ing, (see Strand 2 focus on mechanisms of impact).
Quality of medication review
Review of 105 PCPs, by trial geriatricians, found no
overall safety concerns. They explicitly agreed with or
made no comment for 49 (46.7%) and 36 (34.3%) PCPs
respectively. Seven (6.7%) PCPs were classed as having
‘poor PIP documentation’ and in 13 (12.4%) it was noted
that there were ‘potential missed opportunities’, for ei-
ther a general pharmaceutical care issue or a specific
falls risk.
Strand 2: mechanism of impact (objectives 1,2,3,4)
Medication changes
Therapeutic area There were 373 PCPs returned for
the 449 residents. Of these, three residents withdrew
from the study, so the PCP was not included in the ana-
lysis (n = 370). There were 76 PCPs which were not
available for analysis: 25 residents died before a PCP was
completed, 44 residents where the PIP did not deliver
the intervention, four PCPs were not completed by two
PIPs (reason not given), two residents changed care
homes before a PCP was completed, and one PCP was
lost to follow-up. Of the 370 PCPs analysed, 44 recorded
no medication change. At least one intervention relating
to a resident’s prescribed medicine was reported in 326
PCPs (88.1%).
Across the 370 PCPs analysed, there were 566 inter-
ventions: 284 (50.2%) were to stop a medicine, 95
(16.8%) to reduce a dose, 49 (8.7%) to change a medi-
cine, 60 (10.6%) to start a medicine, 26 (5%) to increase
a dose and 52 (9.2%) to initiate monitoring. The main
therapeutic areas associated with interventions were the
central nervous system 189 (33.5%), cardiovascular 103
(18.2%), gastro-intestinal 89 (15.8%) and blood and nu-
trition 69 (12.2%). Therapeutic areas with fewer inter-
ventions were the endocrine system 41 (7.1%),
respiratory system 24 (4.2%) and skin 23 (4%).
Impact on falls and drug burden A number of medi-
cine changes were related to medicines with a propensity
to affect falls (the primary trial outcome) (n = 185) or
with an associated drug burden (n = 189.
Seventy-seven of these interventions involved stopping
a medicine, and 46 involved reducing the dose of a
medicine with an OR for falls of greater than 1.5. A fur-
ther 15 medicines with a falls OR of 1.51–2 were started
and 16 had a dose increase. There were 179 interven-
tions (31% of interventions) which were associated with
a reduction in DBI score [23] and 10 with a DBI in-
crease, see Table 2.
Interview data indicated that the majority of GPs were
highly supportive of the PIP making medication changes:
‘Having a pharmacist who understands the process of de-
prescribing round the table, is a great asset to our team’,
GP 21. However, two PIPs were hindered in making
Fig. 2 CHIPPS Process evaluation :Topic guide
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medication changes due to reluctance of the GP or care
home staff to endorse this activity: ‘The GP occasionally
re-prescribed things I had stopped- one patient had not
had Gaviscon for over 1 year, so I stopped it and the
week after the GP had put it back on prescription’ PIP
13.
The review of PIP prescribing activity against GP re-
cords at six-month follow-up indicated that the majority
(531, 93.8%) of PIPs introduced changes which remained
in place post-intervention. The highest categories of sus-
tained interventions were for medication discontinuation
(276 [48.8% interventions) followed by dose reduction
(89 [15.7%] interventions).
Potential missed opportunities Of the 185 PCPs
reviewed by the research pharmacists, only 27 (14.6%)
PCPs were considered to have missed a potential oppor-
tunity to make a medication change which could have
reduced the resident’s fall risk. These all related to non-
review of one or more medicines which had an anti-
cholinergic effect; of the 64 occurrences (27 different
medicines), 17.2% had an OR for increased falls risk of
1–1.5, 81.2% of 1.51–2, and 1.6% > 2. A further 38 PCPs
(20.5%) were considered to have missed a potential op-
portunity to optimise the prescribing of other medicines
not associated with a falls risk. This was either a need
for monitoring such as blood tests, no recorded indica-
tion or no recent review. Dates on the reviewed PCPs
also indicated that it was several months after the start
of the intervention before some residents were reviewed
by the PIP. This was confirmed in interviews when PIPs
explained it could be a few weeks before they had
reviewed all residents and it took time to build a rela-
tionship before they could start deprescribing. Where a
PCP was reviewed by the geriatrician and the pharmacist
researcher, there was strong agreement between com-
ments and potential missed opportunities.
PIP support for care home
As part of their role, PIPs could offer general support to
the care home including staff training, and supporting
good quality communication between care home, GP
and community pharmacist.
Services provided and frequency PIP activity logs show
that two-thirds of PIP time was spent on resident-
related activities. Converting the minutes recorded to
approximate hours, this equated to: resident-related
face-to-face activity for 348 h (24% of time); resident-
related desk-based activity 601 h (43% of time); general
tasks for 338 h (24% of time); and travel for 137 h (10%
of time). Additional file 5 reports activity type and dur-
ation across phases.
In the questionnaire responses, eight of the 16 PIPs re-
ported the time allocation as sufficient, three as too
much, and five as not enough. The number of care
homes or number of allocated residents for the PIPs did
not appear to be associated with overall activity time.
Nonetheless where the PIP dealt with more than one
care home, they reported challenges in allocating their
time between sites: ‘I had two care homes so I found
splitting my time between them, when I didn’t have an
even number of participants in each was quite difficult’
PIP2. A couple of PIPs and care home managers re-
ported that towards the end of the intervention, there
seemed little for the PIP to do: ‘I enjoyed that at the be-
ginning, sadly that got a little bit repetitive towards the
end because obviously we’d gone over the same residents
every single week and there wasn’t any more we could
look at ’ CHM 9. However, the majority wanted the
intervention to continue.
PIP training for care home staff PIPs were provided
with six training PowerPoint presentations to deliver to
care home staff. These were not widely used: no PIP
used either the sedative or antibiotic training presenta-
tion; two PIPs used both the laxatives and pain control
training presentation; three PIPs used both the antipsy-
chotics and medicines administration training presenta-
tions. In interviews the main explanation for limited use
was that the care home already had training in place:
‘both of the homes were with [name of supplying organ-
isation] and they do training, a lot of it is online so they’d
access to all that, I would have done it if they wanted,
but didn’t have the need’ PIP 21.
Informal education took place when PIPs worked
alongside care staff advising on medication routines.
Table 2 Medicines interventions with propensity to affect falls
and drug burden
Intervention Falls Odds Ratio.
1–1.5 1.51–2 > 2 All
No (%) of interventions
Stop 17 (18%) 77 (82%) 0 (0%) 94 (100%)
Start 4 (20%) 15 (75%) 1 (5%) 20 (100%)
Dose reduction 8 (15%) 46 (85%) 0 (0%) 54 (100%)
Dose increase 1 (5.9%) 16 (94%) 0 (0%) 17 (100%)
DBI Score
0.1–0.5 0.51–1 1.01–1.5 All
No. (%) interventions
Stop 81 (61.4%) 51 (38.6%) 0 (0%) 132 (100%)
Start 3 (50%) 3 (50%) 0 (0%) 6 (100%)
Dose reduction 26 (55.3%) 21 (44.7%) 0 (0%) 47 (100%)
Dose increase 4 (100%) 0 (0%) 0 (0%) 4 (100%)
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Usefulness of service
In questionnaire responses, when PIPs (n = 16) were
asked whether they agreed the intervention was worth-
while: 3 ‘strongly agreed’, 4 ‘agreed’, 6 ‘neither agreed
nor disagreed’, 2 responded ‘not relevant.’ PIPs were also
asked how satisfied they were with the intervention: 5
‘very satisfied’, 7 ‘satisfied’, 3 neutral’, 1 ‘not at all satis-
fied’. They provided open text responses in the question-
naire and responded to the interview question on the
most and least useful parts of the intervention. There is
no data as to why two PIPs responded ‘not relevant’
when asked about worthwhileness of the intervention.
Open text and interview comments relating to the use-
fulness of the service predominantly related to improved
medication safety, or improved relationships including
contact between PIP and care home staff and residents.
Statements about lack of usefulness predominately
centred on the complexity of research paperwork. Two
PIPs stated ‘A lot of time was spent on a small number
of patients’ and one found working across two care
homes time intensive.
In questionnaire responses, when GPs (n = 8) were
asked whether they agreed the intervention was worth-
while: 1 ‘strongly agreed’, 4 ‘agreed’, 2 ‘neither agreed
nor disagreed’, 1 ‘strongly disagreed. GPs were also
asked how satisfied they were with the intervention:
2‘very satisfied’, 4 ‘satisfied’, 2 ‘neutral’. When the inter-
vention was perceived to be useful it was in factors such
as increasing safety of medicines in care homes and re-
ducing wastage. Changes in practice were reported, in-
cluding in one triad where there had been challenges
with implementation: ‘I actually did start to change my
practice - when I prescribed a cream for a course of treat-
ment I actually put on the directions ‘discard after a
week’ or ‘discard after a fortnight” GP 19. However, the
same GP strongly disagreed that the intervention was
worthwhile in the questionnaire data stating ‘The care
home would not buy into the service and were very angry
and dismissive of any interventions and I was the one
who had to bear their grumbles’ GP 19.
In the two questionnaire responses from care home
managers, both agreed the intervention was worthwhile
and both were satisfied. During Interviews many care
home participants highlighted improved links between
care home and the PIP as useful for the staff: ‘it’s actu-
ally lifted some stress, because when you’re constantly
waiting on calls back and your resident is maybe deteri-
orating, the residents have really benefitted from it, and
that’s what’s important’ CHS 14–1.
Quality of communication
PIP relationship and communication with GPs In
questionnaire responses, PIPs (n = 16) rated their
relationships with GPs as: 11 ‘very good’, 1 ‘good’ and 4
‘neutral’. All who rated it neutral were not employed by
the GP. Interview data suggested several found it diffi-
cult to develop a good relationship within a GP practice
previously unknown to them: ‘level of interaction was
quite minimal … the PIP was able to communicate to me
via computerised system … I don’t really know the PIP to
be honest’ GP 6.
Where the PIP was already employed in the GP prac-
tice, there were established working practices and the
PIP appeared proactive in reducing GP workload, acting
as an autonomous practitioner: ‘the big decisions I told
GP about, the little decisions I didn’t bother telling them,
it was in the notes anyway’ PIP 9.
PIP relationship and communication with care home
managers and staff In questionnaire responses, PIPs
(n = 16) rated their relationships with care home man-
agers as: 9 ‘very good’, 4 ‘good’, 1 ‘neutral’, 2 ‘difficult’.
Where the relationship was difficult, this was associated
with poor communication of study purpose: ‘In the care
home that was even more apparent that they did not
know why I was there for! They said “sorry there is no
one you can talk to”’ PIP 19. Communication was dis-
rupted when the care home manager changed. Eleven
care homes had a change of manager at least once dur-
ing the interventions.
In questionnaire responses, PIPs (n = 16) also rated
their relationships with care home staff as: 5 ‘very good’,
9 ‘good’, 1 ‘neutral’, 1 ‘very difficult’. Lack of continuity
of care staff and challenges in language and understand-
ing affected communication: ‘sometimes I find leaving
messages doesn’t always get a result, … that might be a
result of a disorganised Nursing Home … communication
is difficult, language barriers’ PIP 20.
In a small number of triads, the intervention and role
of the PIP appeared not to be fully understood (or em-
braced). In these homes, either the care home appeared
reluctant to have any outside agencies coming in, or the
care home manager circumvented the PIP to liaise dir-
ectly with the GP. Several PIPs reported being con-
strained in pushing forward substantial system changes
as many homes had good community pharmacy support
and the PIP was aware their time in the home was lim-
ited: ‘I never got to the stage where the (care) home were
calling me about things, … it takes at least six months, if
not a year, to properly integrate; for all the team mem-
bers to trust you especially if they have never had a
pharmacist working for them … they just don’t know
what you do’ PIP 6.
PIP communication with residents and residents’
families Many residents lacked capacity and had com-
munication difficulties. Where PIPs could engage with
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residents in sharing decision-making about medicine re-
view, they reported this as a largely positive experience.
However, the one resident who received regular appoint-
ments with secondary care professionals to manage their
health condition asserted they did not want the PIP
changing their medicines. In interviews, a few care home
staff reported that improvements in the residents’ quality
of life due to changes in medicine were observable and
also appreciated by relatives: ‘I don’t think I have had
any falls from her for a couple of months whereas we
were having three or four a week so that is a huge reduc-
tion … her husband is much more positive about his ex-
periences when he visits her’ CHM 9.
PIP communication with community pharmacies In
questionnaire responses, PIPs (n = 16) rated their rela-
tionships with community pharmacists as: 8 ‘very good’,
3 ‘good’, and 5 ‘neutral’. When the PIP was only in-situ
for the trial there was an acute awareness of not chan-
ging systems already in place: ‘I was very aware that it
was a finite time so I really didn’t want to step on any
toes, whereas if you have already built that relationship,
they know that you are not coming in to judge them’ PIP
19. Where the community pharmacist was known to the
PIP, communication systems were well-established, and
it was seen as a joint endeavour: ‘PIP knows them all
[community pharmacy] they’re a good team’ GP 14.
Strand 3 outcomes (objectives 2,4)
Outcomes of medication review
Medication reviews undertaken in the intervention bene-
fitted care home medicines practice. In interviews, all
PIPs reported reducing medicines with anticholinergic
and sedative activity, rationalising Medicine Administra-
tion Record (MAR) charts, removing no longer-used lo-
tions and ‘as required’ medicines. This activity simplified
ordering and dispensing, and reduced risk of medicines
being inappropriately used or being beyond their recom-
mended expiry date. Several GPs spoke about the PIP
improving safety by having detailed knowledge of
residents.
Perception of service
Perceived improvement to resident care was the overrid-
ing aspect of satisfaction across all stakeholders. Table 3
provides examples of stakeholders’ perception of the
CHIPPS service (Table 3).
At interview all PIPs reported they enjoyed the oppor-
tunity to use their professional skills as an independent
prescriber and to have the time to review medications.
Many also highlighted the positive experience of having
time to be involved with residents and their families.
However, lack of care home staff time and staff turnover
limited the ability of some PIPs to deliver the service: ‘it
was quite difficult because the manager left, and there
was a lot of locum staff in from the agency, and it was
actually quite difficult at times to speak to staff that
knew the patients’ PIP 22.
Several GPs mentioned that it had reduced their work-
load as they could be confident medications were up-to-
date and the PIP responded to care home queries. A
couple of GPs indicated that similar services were
already being routinely implemented: ‘we are going to be
employing a pharmacist as part of the Primary Care Net-
work. It is unsure what their role is going to be, but I
think certainly they will review the patients who have the
most polypharmacy’ GP 8.
All care home managers and staff reported they were
pleased the PIP medicine review led to reduction of
items on the MAR charts which made ordering and dis-
pensing easier, and improved stock control. They appre-
ciated that medication queries were addressed more
swiftly, and they had continuity of contact with one
practice staff member. Many were able to recall im-
provements for residents because of more personalised
medicines review.
Strand 4 contextual factors (objective 1, 2, 6)
A contextual factor that impacted on implementation
was whether the PIP had previously worked in the GP
practice. Where a new relationship had to be developed
there were more reports of uncertainty about role and
challenges in effective communication such as finding
time to meet with the GP and practice staff being un-
aware of the PIP role: ‘I found it very difficult that I was
not an employee of the GP practice. This meant having
to start from scratch building relationships with the lead
GP for the care home … I was not a known entity in the
practice’ PIP 6. There were difficulties getting prompt
access to IT systems which meant PIPs were repeatedly
transferring data across paper and IT systems. Commu-
nication between PIP and GP could be adversely affected
by working patterns, especially if both were part-time,
but the location and size of the GP practice appeared to
have no effect on intervention delivery.
The type and size of care home did not appear to be
important in respect of intervention implementation.
However, when the PIP dealt with more than one home,
they found it difficult to manage their time across sites,
as previously noted. Conversely, another PIP, who had
close links with the care home before the trial, found it
difficult to define any additional activity to undertake
during the trial. Care home staff changes disrupted
relationships.
The facilitators to delivering the intervention centred
on trustful relationships and when each stakeholder
could see improvement in either systems and/or resident
outcomes. The visibility of the PIP in the care home was
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Table 3 Qualitative examples of stakeholder perceptions of the intervention
PIP GP Care homes
Resident
quality of life
‘It was just pushing it a bit further, looking
at the patient as a whole, and being able
to do a little bit more and involved the
families … made me be more thorough
as a prescriber and a pharmacist’ PIP 22
‘A lady was finding it very hard to swallow
medication and I was able to get her
medications changed. Some of them were
de-prescribed and some of them were chan-
ged into a form, a more dispersible form
and she was much happier with that’ PIP 1
‘I don’t have as much time to go round
every single one unless it is doing a Care
Plan. The Pharmacist looked at them and
thought ‘well they have been on this stuff
for a long time’ liaised with the staff and
said ‘look do you think we might be able
to reduce it?’ You know ‘what’s their
behavioural, you know their behaviour
like?’ and then we have trialled reductions
of things and the same with anti-
depressants and things as well’ GP16
‘A lady she didn’t particularly like the
texture and the taste of the chalky Ad Cal
tablets so PIP changed her tablet and that
was a good positive experience for her
because she was engaged’ CHM 1
‘We are having good conversations it is
not just somebody instructing on us what
they think should be done … you are
having that dialogue and explaining
about your resident and the Pharmacist
has taken that into the background of the
resident’s care needs and what the
difficulties have been … it has been a
positive impact’ CHM 12–03
Increased
safety
‘Some patients were on meds and they
hadn’t been necessarily reviewed, so they
were then reviewed, so I’d like to think
that the quality was better … hopefully
the patient care was better’ PIP 2
‘From a safety and medicine waste point
of view things have much improved. Care
home teams greatly appreciated time
taken looking at repeat meds, ensuring
they are up to date, have good
instructions’ GP 3
‘It brings another layer of safety to
prescribing in a care home, because we all
know that that can be a little bit, not
unsafe, but it can be challenging, partly
because there are so many residents with
poly pharmacy’ GP11
‘Just a safety blanket’ CHM 14–02
‘PIP did ensure that the bloods were
taken so that we were getting a true
thyroid reading for the dosage. Diabetics
as well, we did have urine testing and





‘Stock can go out of date and then it is
disposed of and wasted … less of that is
happening now’ PIP 8
‘We have a two-way conversation now.
When medicines change, we tell the phar-
macy so they know to expect the change’
PIP 9
‘It is meant to be on repeat prescription,
you’ve got to go through the rigmarole of
phoning the doctor, they’ve got to phone
you back, that can take ages, and it’s just
a bit of a waste of their time but now the
PIP will make sure that it goes on the
repeat prescriptions, so there’s never an
issue for the next cycle, and things don’t
get missed’ CHM 14–02
Impact on
workload
‘I would have liked to use the training
materials for the care home staff, although
they were all very experienced and one of
the homes was a nursing home with
trained nursing staff. I may still do so if
the opportunity arises or if they feel it
would be beneficial’ PIP 4
‘I want it back! It was very helpful for me;
it did take some of the workload off the
weekly visits that were all about
medication’ GP 16
‘It made ordering easier, a little bit
simpler, put the MAR charts into place a
bit better, in respect of the things that
were on there that were no longer
needed they were taken off and things




‘Really rewarding, as a pharmacy
professional and especially as a Pharmacist
Independent, I can really use my skills to
benefit the Care Home residents directly’
PIP 16
‘I have the confidence to go in and use
the training … I feel confident in their
prescriptions that everything has been
well looked after, so I would be confident
to continue to reauthorize the issue’
PIP 1
‘The care home nurses assessment are
also being taken as a valuable tool as
well,, and the nurses are liaising with the
PIP, to prescribe what they think is
needed, I think it’s a win, win situation,
the nurses are feeling valued, and the PIP
as well’ CHM 21–02
‘I can’t even remember that far back but I
think we already had training, allocated
training, delivered by our Community
Pharmacist in place anyway so I maybe





‘I think the CHIPPS probably works best if
you are actually familiar with the surgery’
PIP 19
‘I found the pharmaceutical care plan
quite cumbersome and I didn’t find it
intuitive, I’ve done medication reviews
and pharmaceutical plans for quite a few
years, and the ones I’ve used a lot more
simplistic, Yes it was very comprehensive,
there was a lot of information stored on it,
‘Occasionally PIP would pick up
something that I would have to then
address and very often when you try and
get blood tests on these patients, they
don’t like it and refuse to let the District
Nurses near them so it just adds, those
little contacts add up and I feel at the end
of it I had achieved nothing’ GP 19
‘It was very useful when there was some
communication between the PIP and
‘She was helpful when here but did not
attend every week’ CHM 6
‘I don’t know that it actually happened
umm the residents in question that
actually agreed to sign up for it their
medication was never really appropriate
for review so that is perhaps why it never
happened’
CHM 18–02
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also an important factor in providing care home staff
with a direct access point for medicine requests and
queries. Barriers to delivery of the intervention centred
on PIP, GP and care home staff ‘s uncertainty about PIP
clinical competence. Care home staff had concerns re-
lated to impact of reducing drugs on residents’ behav-
iour. When there was limited communication between
stakeholders and a lack of clear demarcation between
professional roles PIPs experienced challenges in imple-
menting changes. Figure 3 summarises the barriers and
facilitators.
Discussion
This mixed method process evaluation examined an
intervention that placed pharmacist independent pre-
scribers in UK care homes, they took responsibility for a
resident’s medicines with a primary aim to mitigate risk
of falls in residents and improve their quality of life. A
secondary aim was to promote good practice in medi-
cines management. We found that the CHIPPS interven-
tion could be safely implemented; across all data sets it
was perceived to improve resident care and safety
through direct changes to medicines, and care home
staff valued PIPs being able to respond quickly to medi-
cine queries. These staff also reported improvements in
medication processes related to ordering and storing.
Variation was seen in the experience of PIPs, number
of residents and number of care homes where they deliv-
ered the intervention. Nonetheless, stakeholders re-
ported perceived improvements in medication practice
and improvements were clearly apparent in some resi-
dents’ quality of life. All PIPs, who delivered the inter-
vention, were able to implement most of the essential
elements of the service specification and most PIPs im-
plemented some features of the discretionary elements.
For those PIPs not already embedded in the GP practice,
more barriers were seen, especially as PIPs had a pivotal
role in communicating their role in the care home and
GP practice. In practices where the PIP was employed
their bought-out time supported their additional care
home prescribing activity.
We examined the delivery of the intervention in terms
of quality, quantity, adaptation and variations across tri-
ads. The intervention was consistently delivered, with
PIPs providing essential tasks from the service specifica-
tion to the majority of residents. Variation in delivery
was attributed to resident and care home need. Review
(by PhD student and research team pharmacists) of resi-
dents’ PCPS identified that PIPs had decided no medi-
cine change was required for some residents. Delay in
carrying out review of some residents’ medicines left less
time for any benefits from a medicine change to be
Table 3 Qualitative examples of stakeholder perceptions of the intervention (Continued)
PIP GP Care homes
for a working document for a pharmacist,
it would be alright, but for presenting to a
GP it wouldn’t be any use’ PIP 11
myself, the negative would be it just
didn’t happen enough’ GP 6
Fig. 3 Have a lower case c for coding summary
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captured within the 6months’ study period. The review
of PCPs by the research team pharmacists indicated that
PIPs missed few potential opportunities to change a
medicine, possibly reflecting the appropriateness of the
bespoke, empirically grounded training [14] in giving
PIPs the knowledge and confidence to deliver the
intervention.
The PIPs deprescribed a range of medications and
reviewed PRN medications. This activity reduced the
drug burden for the resident and led to the clearer
MARs charts reported by care home staff. Previous stud-
ies have also reported increased safety of medicine ad-
ministration when a pharmacist has undertaken
medication review [29, 30].
In relation to mechanisms of impact, PIPs rarely deliv-
ered formal training to staff, which was a discretionary
activity in the service specification. PIPs had been pro-
vided with training material designed to enable care
home staff to consider the risk of certain medicines and
the distinct needs of older people, but few delivered this
training due to care homes reporting lack of need. Yet
this might be challenged. For example, the antibiotic
training package was never used, yet antibiotic prescrib-
ing rates are reportedly high in care homes [31], contrib-
uting to the global public health challenge of antibiotic
resistance. Similarly, Coon et al. [32] in a review of inter-
ventions to reduce inappropriate antipsychotic medica-
tions in care homes found staff education effective in
reducing prescribing of these drugs. Further work is
needed to explore the impact of care home staff training
on resident wellbeing, including whether generic training
offered by national providers differs in content and out-
come from training a pharmacist could tailor for a spe-
cific care home.
Several individual components impacted on the per-
ceived effectiveness of the intervention. To enable the
PIP fully to deliver the service specifications, other stake-
holders, primarily the GP and care home staff, had to
understand the PIP role and have confidence in the PIP’s
ability. Successful integrated working requires trust be-
tween health professionals [33]. We found when GPs
had established relationships with the PIP through previ-
ous employment, they were more likely to support
pharmacist independent prescribing. Some GP practices
planned to continue with the expanded pharmacist role
post-intervention, suggesting there was acceptance of
the intervention. When the PIP had not worked with the
GP before, greater negotiation was needed on formalis-
ing the scope of PIP prescribing and where this was not
achieved accounts of the usefulness of the intervention
are more negative from all stakeholders. Our develop-
ment work suggested each person involved in the care of
the resident needed to have a shared understanding of
the professional competencies of the PIP and an
understanding of their role [12], and that GPs would
prefer to work with people who they knew and trusted.
Previous studies have reported that where GPs are not
familiar with pharmacist prescribing initial acceptance of
the role was low [34, 35]. However, increasing demand
on GP workloads has seen exponential growth in phar-
macists within GP practices, so an extension to their role
is likely to be increasingly established [34]. .There will
remain a need to avoid overlap in roles which was iden-
tified as a concern by a small minority of GPs.
Care home teams were predominantly in favour of the
intervention, in particular the ready access to the PIP
which facilitated prompt resolution of any prescription
queries. Tangible positive outcomes are important when
implementing practice change in care homes, particu-
larly where there may be a reluctance to change long-
standing medication [36]. Here the CHIPPS intervention
was successful as PIPs had dedicated time in the care
home each week and care staff had confidence that if
changes in medication were not effective, this could be
readily discussed with the PIP or reversed. A change in
care home managers often led to the leadership in the
care home not ‘buying’ into the intervention. There was
strong evidence that where care home staff were unsure
of the intention of the intervention there was reluctance
to fully engage and there were occasional attempts to
block pharmacist review. This resonates with an evi-
dence synthesis of care home readiness for healthcare
interventions which identified the importance of time to
build relationships and the management style of the care
home manager as being important for successful inter-
vention implementation [37]. The involvement of a resi-
dent’s GP and/or pharmacist is a common factor in
successful implementation of interventions in nursing
homes [38]. .Further research is needed to examine care
home staff’s reluctance to engage with medicines quality
improvement activities, as ‘buy in’ from care homes is
essential for any clinical intervention.
Strengths and limitations
A strength of this evaluation is that we collected data
from three UK countries with different pharmaceutical
and health care systems and therefore, conclusions on
the acceptability of the intervention are likely to be
widely applicable. The questionnaire and interviews were
undertaken after the intervention, but by triangulating
these data with study records (PCPs and activity logs)
we were not solely relying on participants’ recall. Our re-
sults add to the growing evidence that pharmacists can
improve care home medication safety through having
dedicated time to undertake both review of residents’
medicines and care home medication systems [30, 39].
It is likely that those who were recruited to the trial
could be early adopters of new practice and as such,
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more receptive to change and innovation. It is noted that
those who volunteer for interview may have stronger
positive or negative experiences than those who do not.
A review of patients’ opinions when pharmacist consul-
tations were initially instigated in GP practices found pa-
tients had limited understanding of the pharmacist’s role
and often had stronger preference for their own GP ser-
vice, but we were only able to interview one resident, in
part due to COVID-19 restrictions at the end of the
study. Challenges in collecting data from these stake-
holders also lay in the cognitive ability of residents to
consent to interview and relying on care home staff to
be gatekeepers to residents and their family. The views
of residents and families need to be further examined as
there may be differing expectations on who has the clin-
ical expertise to prescribe.
Practice implications
We found that it was acceptable to have a prescribing
pharmacist as a named person with responsibility for
care home resident medicines management; a person
who would also provide a link between care home and
GP. Most stakeholders reported positive outcomes re-
lated to resident well-being and improvements in medi-
cines management. However, there are areas which
could be developed to support implementation of this
role.
The service was set up with each PIP providing one
weekly session to each home. Experience showed that
after residents had been reviewed, care plans had been
implemented, and general medicine management pro-
cesses streamlined, the amount of time required to de-
liver the service diminished. However, as one of the
valued outcomes for the care homes was knowing and
being able to depend on the pharmacist, visits should be
sufficiently regular to maintain that relationship, answer
emerging queries and review the medicines of any new
residents.
As primary care pharmacy provision transitions with
the introduction of Primary Care Networks [40] there
needs to be a more comprehensive consideration of
which health and social care professionals might be best
placed to undertake medicines management with care
home residents. Our study has illustrated that prescrib-
ing pharmacists have the skills to fulfil this role, and
GPs and care home staff are likely to find this accept-
able. PIPs liaised with community pharmacists to discuss
medicines management, MAR chart errors and to keep
them informed of medicine changes, thereby ensuring
efficient medicine ordering. While some PIPs undertook
store cupboard stock control, this activity might be more
cost-effective for a pharmacist technician to carry out.
The roles of community pharmacists and pharmacy
technicians need to be considered when planning
pharmacist-led care home medication management.
Interlinked IT systems would streamline clinical
reporting and reduce duplication. PIPs often worked on
paper records in care homes, having to manually transfer
all activity into electronic GP databases. Furthermore,
interlinked IT systems would enable other members of
the primary care team, such as community nurses and
paramedics, to access up-to date resident medicine in-
formation. Such improved communication across the
multidisciplinary team could potentially enhance future
quality of care for residents.
Conclusion
This process evaluation has found that the CHIPPS
intervention, giving a pharmacist independent prescriber
responsibility for management of care home residents’
medicines, can be successfully implemented as intended.
The evaluation found no serious adverse effects when
pharmacists led on prescribing and deprescribing and in-
deed, care home staff often perceived an improved qual-
ity of life in residents, and most were fully supportive of
the intervention. There was widespread deprescribing
across therapeutic areas, with a number of medicine
changes related to medicines with a propensity to affect
falls. Generally, GPs and care home staff had confidence
in the pharmacist’s competence and there was general
agreement that this was a useful intervention, which in-
creased medicine safety Where the PIP had not worked
previously with the GP, they needed to actively build the
relationship as without this the PIP experienced barriers
and resistance to their role in GP practices and care
homes.
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